Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPeSino
2023-505917-25-00Phase 2Authorised
- Sponsor
- Istituti Clinici Scientifici Maugeri
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in sinonasal undifferentiated carcinoma (SNUC), sponsored by Istituti Clinici Scientifici Maugeri. Primary endpoint: Neoadjuvant therapy objective response rate. Planned start Oct 2023; status: authorised.
02
Drugs
03
Conditions
sinonasal undifferentiated carcinoma (SNUC)
Beyond the preview
Go deeper on 2023-505917-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505917-25-00.